This is an aggregated industry headline. Read the full story at Pharmaceutical Technology →
Ratio Therapeutics secures $70m Series C funding for cancer radiotherapy
Ratio Therapeutics, a US-based developer of radiopharmaceuticals for cancer treatment, has closed a $70m Series C financing round.
By Pharmaceutical Technology
· Aug 3, 2026
· via Pharmaceutical Technology
Image: Pharmaceutical Technology
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlinePharmaceutical Technology
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Combining the two drugmakers would trigger severe regulatory concerns and significant pipeline disruptions, co…
The WeekFierceBiotech ↗
Combining the two drugmakers would trigger severe regulatory concerns and significant pipeline disruptions, co…
The WeekBriefing
Three Asia-linked developments stood out: a CEO exit at Legend, a quickly deleted Merck trial posting, and an …